曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的临床效果

Clinical efficacy of Trimetazidine combined with Metoprolol Succinate in the treatment of coronary heart disease with heart failure

目的探讨曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭的临床效果。方法选取我院2015年2月～2017年3月收治的100例冠心病心力衰竭患者作为研究对象,按照区组随机化法分为实验组(n=50)和对照组(n=50),对照组在基础治疗上接受琥珀酸美托洛尔治疗,实验组则在基础治疗上接受曲美他嗪联合琥珀酸美托洛尔治疗,比较两组冠心病心力衰竭患者的治疗效果、血压、心率(HR)、左心射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、血浆脑钠尿肽(BNP)以及不良反应总发生率。结果实验组的总有效率为96.00%,高于对照组的82.00%,差异有统计学意义(P<0.05)。实验组患者治疗后的血压、HR、LVESD、LVEDD水平低于对照组,LVEF、血浆BNP水平高于对照组,差异有统计学意义(P<0.05)。实验组的不良反应总发生率为8.00%,低于对照组的40.00%,差异有统计学意义(P<0.05)。结论冠心病心力衰竭患者接受曲美他嗪与琥珀酸美托洛尔联合治疗,可提高治疗效果,改善其心功能,且用药安全性较高。

Objective To investigate the clinical effect of Trimetazidine combined with Metoprolol Succinate in the treatment of coronary heart disease(CHD)with heart failure.Methods A total of 100 CHD patients with heart failure treated in our hospital from February 2015 to March 2017 were selected,they were divided into the experimental group(n=50)and the control group(n=50)according to block randomization method.The control group received Metoprolol Succinate on the basis of basic treatment,while the experimental group received Trimetazidine and Succinate on the basis of basic treatment.The therapeutic effects,blood pressure,heart rate(HR),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),plasma brain natriuretic peptide(BNP)and the incidence rate of adverse reactions were compared between the two groups.Results The total effective rate(96.00%)in the experimental group was higher than that in the control group(82.00%),and the difference was statistically significant(P<0.05).The blood pressure,heart rate,LVESD and LVEDD levels in the experimental group were lower than those in the control group,and the levels of LVEF and BNP in plasma in the experimental group were higher than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the experimental group(8.00%)was lower than that in the control group(40.00%),the difference was statistically significant(P<0.05).Conclusion Trimetazidine combined with Metoprolol Succinate can improve the therapeutic effect and cardiac function of CHD patients with heart failure,and it is safe to use Trimetazidine and Metoprolol Succinate.